Evidence for Widespread Axonal Damage at the Earliest Clinical Stage of Multiple Sclerosis
Brain 126:433-437, Filippi,M.,et al, 2003
Validation of Diagnositc Magnetic Resonance Imaging Criteria for Multiple Sclerosis and Response to Interferon B1a
Ann Neurol 53:718-724, Barkhof,F.,et al, 2003
Antimyelin Antibodies as a Predictor of Clinically Definite Multiple Sclerosis After a First Demyelinating Event
NEJM 349:139-145,107, Berger,T.,et al, 2003
High- and Low-Risk Profiles for the Development of Multiple Sclerosis Within 10 Years After Optic Neuritis
Arch Ophthalmol 121:944-949, Optic Neuritis Study Group, 2003
The Utility of MRI in Suspected MS, Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 61:602-611,596, Frohman,E.M.,et al, 2003
Spinal Cord MRI in Clinically Isolated Optic Neuritis
JNNP 74:1577-1580, Dalton,C.M.,et al, 2003
A Longitudinal Study of Abnormalities on MRI and Disability From Multiple Sclerosis
NEJM 346:158-164,199, Brex,P.A.,et al, 2002
Interferon Beta-1a for Early Multiple Sclerosis: CHAMPS Trial Subgroup Analyses
Ann Neurol 51:481-490, Beck,R.W.,et al, 2002
Application of the New McDonald Criteria to Patients with Clinically Isolated Syndromes Suggestive of Mulitple Sclerosis
Ann Neurol 52:47-53, Dalton,C.M.,et al, 2002
Progressive Ventricular Enlargement in Patients with Clinically Isolated Syndromes is Associated with the Early Development of Multiple Sclerosis
JNNP 73:141-147, Dalton,C.M.,et al, 2002
MRI Predictors of Early Conversion to Clinically Definite MS in the CHAMPS Placebo Group
Neurol 59:998-1005, CHAMPS Study Group, 2002
Management of Acute Optic Neuritis
Lancet 360:1953-1962, Hickman,S.J.,et al, 2002
Effect of Early Interferon Treatment on Conversion to Definite Multiple Sclerosis: A Randomised Study
Lancet 357:1576-1582,1547, Comi,G.,et al, 2001
Recommended Diagnostic Criteria for Multiple Sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis
Ann Neurol 50:121-127, McDonald,W.I.,et al, 2001
14-3-3 Protein in the CSF as Prognostic Marker in Early Multiple Sclerosis
Neurol 57:722-724, Martinez-Yelamos,A.,et al, 2001
Isolated Demyelinating Syndromes: Comparison of CSF Oligoclonal Bands and Different MR Imaging Criteria to Predict Conversion to CDMS
Mult Scler 7:359-363, Tintore,M.,et al, 2001
Assessing the Risk of Early Multiple Sclerosis in Patients with Clinically Isolated Syndromes: the Role of a Follow Up MRI
JNNP 70:390-393, Brex,P.A.,et al, 2001
Isolated Demyelinating Syndromes: Comparison of Different MR Imaging Criteria to Predict Conversion to Clinically Definite Multiple Sclerosis
AJNR 21:702-706, Tintore,M.,et al, 2000
Multiple Sclerosis--From Probable to Definite Diagnosis
Arch Neurol 57:974-979,930, Achiron,A. & Barak,Y., 2000
Intramuscular Interferon Beta-1a Therapy Initiated During a First Demyelinating Event in Multiple Sclerosis
NEJM 343:898-904, Jacobs,L.D. et al, 2000
Cisplatin Neurotoxicity Presenting as Reversible Posterior Leukoencephalopathy Syndrome
AJNR 19:415-417, 5911998., Ito,Y.,et al, 1998
Brain Infarction Following 5-Fluorouracil and Cisplatin Therapy
Neurol 52:899-901, Amrani,M.E.,et al, 1998
Regional Subacute Cranial Neuropathies Following Internal Carotid Cisplatin Infusion
Neurol 47:1088-1090, Alderson,L.M.,et al, 1996
Peripheral Neuropathy from Taxol and Cisplatin Combination Chemotherapy:Clinical and Electrophysiological Studies
Ann Neurol 35:304-311, Chaudhry,V.,et al, 1994
Intra-arterial Cisplatin-Associated Optic and Otic Toxicity
Arch Neurol 49:83-86, Maiese,K.,et al, 1992
Cisplatin Neurotoxicity
NEJM 323:64-65, Lindeman,G.,et al, 1990
Autonomic Neuropathy After Treatmant with Cisplatin, Vinblastine, and Bleomycin for Germ Cell Cancer
BMJ 300:511-512, Hansen,S.W., 1990
Prevention of Cisplatin Neurotoxicity with an ACTH (4-9) Analogue in Patients with Ovarian Cancer
NEJM 322:89-94, 126-1271990., Gerritsen Van Der Hoop,R.,et al, 1990
Decreased Phenytoin Levels in Patients Receiving Chemotherapy
Am J Med 87:505-510, Grossman,S.A., 1989
Unusual Presentation of Cis-Platinum Neuropathy
Neurol 38:488-490, Mollman,J.E.,et al, 1988
Visual System Toxicity Following Intra-arterial Chemotherapy
Neurol 38:284-289, Kupersmith,M.J.,et al, 1988
Regional Nerve Injury After Intra-Arterial Chemotherapy
Neurol 37:834-837, Castellanos,A.M.,et al, 1987
Cisplatin Neuropathy with Lhermitte's Sign
JNNP 49:96-99, Dewar,J.,et al, 1986
Peripheral Sensory Neuropathy & Cisplatin Chemotherapy
Neurol 34:934-938, Roelofs,R.I.,et al, 1984
Cisplatin Neuropathy
Cancer 54:1269-1275, Thompson,S.W.,et al, 1984
Neurotoxic Effects of Cisplatin Therapy
Arch Neurol 39:719-720, Walsh,T.J.,et al, 1982
Cis-diamminedichloroplatinum (II) , A New Anticancer Drug
Ann Int Med 86:803-812, Rozencweig,M.,et al, 1977
Diabetes Insipidus As A First Manifestation In Multiple Sclerosis
, Thouvenot, E.,et al,